Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Med Virol ; 78(12): 1572-8, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17063509

RESUMEN

The key to developing a therapeutic vaccine for chronic hepadnavirus infection lies in the characteristics of the host-immune response which leads to clearance of acute infection. Groups of 28-day-old ducks which had been surgically bursectomized (n = 10) or thymectomized (n = 13) on the day of hatch or were untreated (n = 21) were inoculated with 10(9) viral genome equivalents (vge) DHBV, then bled twice a week, and euthanased 40 days later. Serum and liver were tested for DHBV DNA and total leukocytes and peripheral blood mononuclear cells (PBMCs) counted. Liver and spleen sections were either stained with hematoxylin and eosin, and graded for inflammation or stained with peroxidase-labeled anti-human CD3 antibody and examined for T lymphocyte distribution. PBMC counts were similar in all groups. DHBV infection combined with bursectomy increased significantly, while thymectomy decreased significantly the total leukocyte count. The spleen and liver bursectomy increased T lymphocyte number while B cells were decreased. Converse changes were observed in thymectomized ducks. Histological evidence of hepatitis was present in infected control and bursectomized ducks but not in the uninfected control or infected thymectomized ducks. In control animals, DHBV challenge caused viremia in 17 and persistent infection in 11 (56%). Fewer thymectomized ducks (3/13, 23%) and significantly more (100%) bursectomized ducks remained persistently infected (P < 0.001). Unexpectedly, bursectomy led to persistence of infection while clearance of infection occurred normally in thymectomized ducks despite decreased T lymphocyte numbers. This suggests that clearance requires T and B lymphocyte collaboration.


Asunto(s)
Bolsa de Fabricio/cirugía , Infecciones por Hepadnaviridae/inmunología , Virus de la Hepatitis B del Pato/aislamiento & purificación , Hepatitis Viral Animal/inmunología , Inflamación/inmunología , Hígado/fisiopatología , Timectomía , Animales , Linfocitos B/inmunología , Bolsa de Fabricio/inmunología , Femenino , Infecciones por Hepadnaviridae/virología , Hepatitis Viral Animal/virología , Recuento de Leucocitos , Hígado/inmunología , Hígado/patología , Masculino , Bazo/patología , Linfocitos T/inmunología
2.
J Virol Methods ; 137(1): 160-3, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16808980

RESUMEN

Many viruses including HIV, hepatitis C and hepatitis B, have an outer lipid envelope which maintains inserted viral peptides in the "correct" functional conformation and orientation. Disruption of the lipid envelope by most solvents destroys infectivity and often results in a loss of antigenicity. This communication outlines a novel approach to viral inactivation by specific solvent delipidation which modifies the whole virion rendering it non-infective, but antigenic. Duck hepatitis B virus (DHBV) was delipidated using a diisopropylether (DIPE) and butanol mixture and residual infectivity tested by inoculation into day-old ducks. Delipidation completely inactivated the DHBV (p < 0.001). Delipidated DHBV was then used to vaccinate ducks. Three doses of delipidated DHBV induced anti-DHBs antibody production and prevented high dose challenge infection in five out of six ducks. In comparison, five of six ducks vaccinated with undelipidated DHBV and four of four ducks vaccinated with glutaraldehyde inactivated DHBV were unprotected (p < 0.05). Although this solvent system completely inactivated DHBV, viral antigens were retained in an appropriate form to induce immunity. Delipidation of enveloped viruses with specific organic solvents has potential as the basis for development of vaccines.


Asunto(s)
Antígenos Virales/inmunología , Éteres/farmacología , Virus de la Hepatitis B del Pato/efectos de los fármacos , Virus de la Hepatitis B del Pato/fisiología , Vacunas contra Hepatitis Viral , Inactivación de Virus , Animales , Anticuerpos Antivirales/sangre , Modelos Animales de Enfermedad , Patos , Infecciones por Hepadnaviridae/prevención & control , Virus de la Hepatitis B del Pato/inmunología , Hepatitis Viral Animal/prevención & control , Modelos Animales , Solventes/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA